QLT announces interim results of radical study evaluating Visudyne combination therapy Dec 16, 2008
Based on the six-month data review for Visudyne combination therapy and the DSMC's recommendation, the study will continue as planned (Canada Newswire)
QLT announces commencement of tender offer Dec 5, 2008
VANCOUVER, Dec. 5 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced that it will mail an offer to purchase and issuer bid circular (the "Circular") to its shareholders today in connection with a modified "Dutch Auction" tender offer for up to US$50 million of common shares, previously announced on December 1, 2008 ... About QLT QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies ... QLT Inc. is listed on The... (Canada Newswire)
QLT profit rises to $146.9-million Oct 28, 2008
VANCOUVER QLT Inc. profit rose to $146. 9-million in the third quarter from a year-ago earnings of $351,000. (Globe and Mail -- Business)
Fed announces rate decision, Wednesday Oct 25, 2008
QLT Inc. posts third-quarter results. BP PLC reports on the third quarter. (Globe and Mail -- Business)
QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc. Aug 26, 2008
VANCOUVER, Aug. 26 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that QLT USA, Inc., its wholly-owned subsidiary, has entered into an exclusive license agreement with Reckitt Benckiser Pharmaceuticals Inc. for its Atrigel(R) sustained-release drug delivery technology, except for certain rights being retained by QLT USA and its prior licensees ... About QLT QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of... (PR Newswire)
QLT licenses technology to Reckitt Benckiser Aug 26, 2008
VANCOUVER QLT Inc. has licensed its Atrigel sustained-release drug delivery technology for $25-million (U.S.) up-front payment plus up to $5-million in milestone payments. Reckitt Benckiser Pharmaceuticals Inc. gets exclusive licence rights to the technology, except for certain rights being retained by QLT.. (Globe and Mail -- Business)
Study Lets Teens Sound off on Acne Therapies Aug 20, 2008
Corresponding author Dr. Lee T. Zane has participated on advisory boards for Connetics Corp., Stiefel Laboratories Inc., Medicis Pharmaceutical Corp., and QLT Inc., and now works for Anacor Pharmaceuticals Inc.. These types of patient questionnaires can help improve patient care, Dr. Marta J. VanBeek, of the University of Iowa Hospitals and Clinic, wrote in an accompanying editorial. (MEDLINEplus)
QLT announces redemption of 3% convertible senior notes due 2023 Aug 11, 2008
VANCOUVER, Aug. 11 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it is exercising its right to redeem on September 15, 2008 all $172 ... About QLT QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies ... QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc. Atrigel is a registered trademark of QLT USA, Inc. Visudyne is a registered trademark of Novartis AG. Eligard is a registered... (Canada Newswire)
QLT announces second quarter results for 2008 Jul 29, 2008
UPCOMING EVENTS On August 5, 2008 Bob Butchofsky, CEO, will be giving a corporate presentation at the BMO Capital Markets Focus on Healthcare Conference, New York, NY. About QLT QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies ... Conference call information QLT Inc. will hold an investor conference call to discuss second quarter 2008 results on Tuesday, July 29, 2008 at 8:30 a.m. ET (5:30 a.m. PT) ... QLT Plug... (Canada Newswire)
C.A. Bancorp Canadian Realty Finance Corporation Files Preliminary Prospectus for Tax-Efficient 7.6% Yielding Class A Shares and Warrants to Purchase Series 1, Preferred Shares Jul 24, 2008
--------------------------------------------------------------------------- Name Ticker --------------------------------------------------------------------------- Canadian Common Shares Eligible for Exchange --------------------------------------------------------------------------- Agnico-Eagle Mines Ltd. AEM --------------------------------------------------------------------------- Agrium Inc. AGU --------------------------------------------------------------------------- Bank of Montreal... (CCNMatthews Press Releases)
QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million Jun 9, 2008
VANCOUVER, June 9 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that QLT USA, Inc., its wholly-owned subsidiary, has entered into an asset purchase agreement with Allergan Sales, LLC, a wholly-owned subsidiary of Allergan, Inc. (NYSE: AGN) to fully divest QLT's worldwide rights to Aczone(R), a prescription topical medicine approved in the United States and Canada for the treatment of acne vulgaris ... About QLT QLT Inc. is a global biopharmaceutical company dedicated to the... (Canada Newswire)
QLT sells acne treatment product to Allergan Jun 9, 2008
Struggling Vancouver drug-maker QLT Inc. has struck a long-awaited deal to sell its Aczone acne treatment for $150-million (U.S.), three months after U.S. regulators waived an onerous blood-test requirement for the topical medicine. QLT said Monday it will receive a one-time cash payment from Allergan Sales LLC, a unit of Allergan Inc. of Irvine, Ca., upon the deal's closing, which is expected to occur in the third quarter. (Globe and Mail -- Business)
QLT Inc. announces agreement for sale of real estate May 16, 2008
VANCOUVER, May 15 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it has signed a sale and purchase agreement to sell the land and building comprising its corporate headquarters and an adjacent undeveloped parcel of land in Vancouver, British Columbia ... About QLT QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies ... QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.... (PR Newswire)
QLT reports initial proof of concept data for punctal plug delivery technology May 12, 2008
Small study supports the potential for QLT's drug elution technology to reduce and sustain intraocular pressure VANCOUVER, May 12 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today results from a proof of concept trial conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc., of its punctal plug drug delivery technology ... About QLT QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies ... QLT Plug... (Canada Newswire)
QLT completes enrollment in the RADICAL study May 5, 2008
VANCOUVER, May 5 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced it has completed enrolling 160 patients in the Company's Phase II RADICAL trial to determine if combination therapy with Visudyne(R) reduces retreatment rates compared with an anti-VEGF antibody while maintaining similar vision outcomes and an acceptable safety profile ... About QLT QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies ...... (Canada Newswire)
QLT initiates phase II study of punctal plug drug delivery system for glaucoma & ocular hypertension Mar 31, 2008
VANCOUVER, March 31 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today the initiation of patient recruitment into its "CORE" study, a phase II trial being conducted by QLT's wholly-owned subsidiary, QLT Plug Delivery, Inc. ("QPD"), to evaluate the preliminary efficacy and safety of its latanoprost punctal plug delivery system for the treatment of glaucoma and ocular hypertension ... QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and... (PR Newswire)
QLT jumps as regulators clear way for sale of U.S. unit Mar 18, 2008
Stock in struggling Vancouver pharmaceutical company QLT Inc. surged Monday morning after U.S. regulators removed a blood testing requirement from its Aczone acne treatment. The announcement of the decision boosted QLT stock by more than 50 per cent in morning trading, as the stock rose to around $3. (Globe and Mail -- Business)
QLT, Cardiome Pharma stocks jump on good news Mar 18, 2008
VANCOUVER - Vancouver biotech companies QLT Inc. and Cardiome Pharma bucked jittery stock markets Monday as positive news for their drug products sent shares in both companies soaring. Shares in QLT climbed more than 56 per cent to $3. (Canada.com)
Doctors `Repeatedly or Deliberately' Break FDA Rules, Continue Drug Trials Mar 1, 2008
The treatment was developed by Atrix Laboratories Inc., which has since been acquired by Vancouver-based QLT Inc. Sanofi-Aventis SA, the Paris-based drugmaker, markets the medicine in the U.S.. Vestal was one of 22 researchers who signed up 111 U.S. patients to test the new version. (Bloomberg)
QLT co-founder leaving company Jan 20, 2008
VANCOUVER -- QLT Inc. co-founder Julia Levy and several senior managers will be leaving the pharmaceutical company along with about half the staff, whose jobs have been cut in a radical restructuring. Ms. Levy, who launched the Vancouver biotech firm in 1981 based on her pioneering work in light-activated drugs, had stepped back from managerial roles in recent years but remained executive chairwoman of QLT's scientific advisory committee. (Globe and Mail)
QLT founder Levy among those departing Jan 19, 2008
VANCOUVER QLT Inc. disclosed Friday that co-founder Julia Levy and several executives are among 115 people leaving the company in a downsizing announced Wednesday. The job cuts represent 45 per cent of the drug developer's employee count, and it said Friday that further reductions in force are expected in 2008 as the company's assets are divested under the restructuring. (Globe and Mail -- Business)
QLT slashes staff Jan 19, 2008
Vancouver-based pharmaceutical firm QLT Inc. said on Friday it would lay off close to half its workforce of about 260 people. Plagued by a slumping top line and share price, the company said on Wednesday it would put its U.S. operations up for sale. (Financial Post)
QLT reports 40 per cent decline Visudyne blindness treatment Jan 18, 2008
VANCOUVER - QLT Inc. (TSX:) reported a nearly 40 per cent drop in sales of its eye drug Visudyne on Thursday, as the company continued to work on a plan to sell off assets and restructure its business. The Vancouver-based company said sales of Visudyne, a treatment for age-related macular degeneration, a major cause of blindness among the elderly, sank 39 per cent to US$214. (Canoe.ca)
QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2007 Jan 17, 2008
VANCOUVER, Jan. 17 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of US$45 ... QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies ... Conference call information QLT Inc. will hold an investor conference call to discuss year end results for 2007 on Thursday, February 21 at 8:30 a.m. ET (5:30 a.m. PT). (PR Newswire)
QLT Inc. announces initial steps in strategic restructuring Jan 17, 2008
VANCOUVER, Jan. 16 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced that following a months-long business and portfolio review, the Board of Directors has decided to implement several new initiatives designed to enhance shareholder value ... "We are focused on achieving these important clinical milestones and are excited about their potential to create significant shareholder value." About QLT QLT Inc. is a global biopharmaceutical company dedicated to the discovery,... (PR Newswire)
Visudyne sales tumble at QLT Jan 17, 2008
VANCOUVER QLT Inc., which said late Wednesday it plans to sell its U.S. operations and cut about half of its work force, is reporting more bad news. Sales of QLT's Visudyne eye treatment declined by 40. (Globe and Mail -- Business)
QLT investors get some relief Nov 30, 2007
Shares of QLT Inc. leaped 24 per cent yesterday after the Vancouver pharmaceutical company said it is considering a sale of all or part of its business. The struggling biotech firm, hit by declining sales of one of its key products, has been under pressure from at least one major shareholder to cut spending and consider an asset sale. (Globe and Mail)
QLT Board authorizes exploration of strategic alternatives to enhance near- to mid-term shareholder value Nov 28, 2007
VANCOUVER, Nov. 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today announced that the Board of Directors has formed a Special Committee to review all strategic alternatives available to the Company ... Boyd Clarke, QLT's Chairman, said, "The Board of Directors believes that the net value of the assets of the Company exceeds the value represented by the stock price. We had hoped to address that disconnect through the deployment of our current strategic plan. However, as the gap... (PR Newswire)
QLT Puts Self Up for Sale as Drugmaker's Shares Languish Near One-Year Low Nov 28, 2007
Nov. 28 (Bloomberg) -- QLT Inc., the Canadian drugmaker that works with Novartis AG on eye treatments, put itself up for sale after the board said its business plan isn't working. The board is reviewing proposals from several investment bankers and hired Morrison & Foerster, LLP as legal counsel to help the search, the Vancouver-based company said today in a PRNewswire statement. (Bloomberg -- Canada)
QLT puts itself up for sale Nov 28, 2007
VANCOUVER Drug company QLT Inc. is signalling it's for sale as a special committee has been formed to review all strategic alternatives in the wake of falling revenue and a weak stock price. The firm's lead products are eye drug Visudyne, for macular degeneration, and Eligard, a prostate cancer therapy. (Globe and Mail -- Business)
QLT buys ForSight eye co. for $42 million Oct 11, 2007
NEW YORK (Reuters) - Vancouver-based eye products maker QLT Inc. (QLT.TO: ) (QLTI.O: ) on Tuesday said it agreed to buy ForSight Newco II, a drug development company, for an initial payment of $42 million in a bid to expand its product line. ForSight is developing proprietary products including an ocular drug-delivery system targeting glaucoma which has the potential for "multi-product opportunities," said QLT.. (Reuters Canada)
QLT to buy forsight eye company for $42 million Oct 10, 2007
Shares in QLT Inc. dropped to a new 52-week low Monday on news the Vancouver company is acquiring California's ForSight Newco II in a $42 million US deal that includes rights to a drug delivery system that can be used in treating a number of eye conditions. The deal could reach $100 million with future milestone payments including $5 million on the initiation of a phase III clinical trial for the first product using the drug delivery system, called "punctal plugs;" $20 million on the... (Vancouver Sun)
QLT acquires leading edge ocular drug delivery system from ForSight Labs Oct 9, 2007
VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it has entered into an agreement under which QLT will acquire privately held ForSight Newco II, Inc. The acquisition includes ForSight Newco II's proprietary ocular punctal plug drug delivery system with the potential for future multi-product opportunities ... About QLT Inc. QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative... (PR Newswire)
ForSight Labs Announces Acquisition of ForSight Newco II by QLT, Inc. Oct 9, 2007
Oct. 9 /PRNewswire/ -- ForSight Labs LLC announced today that its second spin out company, privately held ForSight Newco II, Inc., has entered into an agreement to be acquired by QLT Inc. (Nasdaq: QLTI; TSX: QLT) ... About QLT, Inc. QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies ... QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading... (PR Newswire)
HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes Sep 18, 2007
NEW YORK, Sept. 17 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today has been informed that Standard s, the official calculating agent for the HealthShares(TM) Indexes, has performed the quarterly rebalancing on the Indexes. The following securities will be added and deleted in the Indexes effective before the opening of trading on the New York Stock Exchange September 21, 2007. (PR Newswire)
Eligard(R) six-month formulation successfully completes European approval procedure Aug 31, 2007
VANCOUVER, Aug. 31 /PRNewswire-FirstCall/ - QLT USA, Inc., a subsidiary of QLT Inc. (NASDAQ: ; TSX: QLT), announced today that the European approval procedure for the Eligard(R) 45 mg six-month formulation was successfully completed ... "The six-month formulation provides physicians with a new convenient option for patients with prostate cancer," said Bob Butchofsky, President and Chief Executive Officer of QLT Inc. "Eligard sales have been strong recently and we believe that this new approval... (PR Newswire)
QLT says Novartis reports sales of Visudyne drop 37.8% Jul 17, 2007
VANCOUVER QLT Inc. says partner Novartis AG is reporting global sales of QLT's Visudyne eye treatment fell 37. 8 per cent to $59. (Globe and Mail -- Business)
QLT loses patent case, ordered to pay royalties Jul 12, 2007
QLT Inc., a maker of eye-disease treatments, is on the hook for more more than $70 million (U.S.) in past penalties and tens of millions of dollars for future sales of its Visudyne drug in the wake of a legal decision by a U.S. district court yesterday. U.S. District Judge William Young yesterday approved a jury's advisory decision reached in November that the Vancouver company should pay royalties of about 3 per cent on Visudyne sales to the Massachusetts Eye and Ear Infirmary, which helped... (Toronto Star)
QLT on hook for millions after court ruling Jul 11, 2007
Biopharmaceutical firm QLT Inc. said Tuesday a U.S. court decision could leave it liable to pay about $69. 6-million (U.S.), plus royalties of 3. (Globe and Mail -- Business)
QLT USA, Inc. files Aczone(TM) labeling supplement for removal of blood screening requirement May 29, 2007
VANCOUVER, May 29 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that QLT USA, Inc. submitted a labeling supplement (sNDA) for Aczone(TM) to the U.S. Food and Drug Administration (FDA) to request the removal of the gluceose-6-phosphate dehydrogenase (G6PD) screening and blood monitoring requirements from its current label ... QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies ... QLT... (PR Newswire)
The party will end. Take two minutes to prepare May 12, 2007
Sure you'll miss out on hot growth stories like Research In Motion Ltd. by insisting on dividends, but you'll also be saved from the likes of Nortel Networks Corp., QLT Inc. and Celestica Inc., all of which were major contributors to the big loss turned in by the original Two-Minute Portfolio in 2002. The two-minute strategy is supposed to be both simple to execute and cheap to operate because there are no management fees as there are with mutual funds. (Globe and Mail -- Business)
QLT strengthens its expertise in ocular by adding David A. Saperstein M.D. as interim Chief Medical Officer and Paul L. Kaufman M.D. as Head of the Ocular Scientific Advisory Board May 1, 2007
VANCOUVER, May 1 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that David A. Saperstein, M.D. will be joining QLT as a consultant and interim Chief Medical Officer and Paul L. Kaufman, M.D. as Head of our Ocular Scientific Advisory Board. "We are very pleased to be able to attract these internationally highly regarded experts in ophthalmology to help us assess and develop new treatments for ocular diseases," said Bob Butchofsky, President and Chief Executive Officer... (PR Newswire)
Dow surges past 13,000 Apr 26, 2007
A funny thing happened on the way to QLT Inc. reporting first-quarter results on Wednesday, even though they were pretty much in line with analysts' forecasts: the numbers were released a day early. The unexpectedly early reporting of the quarter may be seen as indicative of something positive on the horizon such as a take-out or the settlement of the Massachusetts Eye and Ear Infirmary patent dispute, writes Westwind Partners analyst Aaron Bennett. (Globe and Mail)
QLT sees Europe curbs on Visudyne use;profit drops Apr 26, 2007
TORONTO, April 25 (Reuters) - QLT Inc. (QLT.TO: , ) said on Wednesday that the Committee for Medicinal Products for Human Use will recommend to the European Commission that its Visudyne treatment not be used for occult subfoveal choroidal neovascularization. But the company could not say what impact the decision would have on its European sales of Visudyne, which is used in the treatment of age-related macular degeneration. (Reuters)
QLT announces Q1 results for 2007 Apr 25, 2007
Conference Call Scheduled for April 25 at 8:30 a.m. Eastern Time VANCOUVER, April 24 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) today reported financial results for the first quarter ended March 31, 2007 ... About QLT QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies ... Updated Conference Call Information QLT Inc. will hold an investor conference call to discuss first quarter 2007 results on... (PR Newswire)
QLT announces that CHMP will recommend to the European Commission that occult indication be deleted from the Visudyne(R)label in European Union Apr 25, 2007
Other Visudyne indications not affected by the CHMP Opinion VANCOUVER, April 25 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it has been informed that the Committee for Medicinal Products for Human Use (CHMP) will recommend to the European Commission that the indication of the use of Visudyne(R) in the treatment of occult subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) be deleted ... Conference call information QLT Inc. will hold... (Canada Newswire)
QLT announces first quarter 2007 Visudyne(R) sales Apr 23, 2007
VANCOUVER, April 23 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of US$61 ... "Sales of Visudyne in the U.S. appear to have stabilized in January and grew in February and March due to increases in market share of combination therapy," said Bob Butchofsky, President and Chief Executive Officer of QLT Inc. "Visudyne average daily sales were 105 vials in January, but average daily sales... (PR Newswire)
Bank of Canada sets rate Apr 21, 2007
QLT Inc. releases first-quarter results. Analysts expect profit of 8 cents a share, down from 16 cents a year earlier. (Globe and Mail -- Business)
Deals: just what the Street needed Apr 20, 2007
Long-suffering backers of QLT Inc. finally have something to cheer about after UBS Securities upgraded the stock to neutral from reduce, judging it is now fairly valued in the context of our sum-of-the-parts valuation. QLT closed at $7. (Globe and Mail -- Business)
QLT settles 2001 patent lawsuits with Massachusetts Eye and Ear Infirmary Mar 5, 2007
VANCOUVER QLT Inc. settles 2001 patent lawsuits with Massachusetts Eye and Ear Infirmary, but one remains. More to come. (Globe and Mail -- Business)
CNW Group Daybook for Thursday, February 22, 2007 ALL TIMES ARE LOCAL Feb 22, 2007
D., Vice President, Corporate Communications, (450) 680-4572 URL: TIME: 08:30 Eastern EVENT: QLT INC. INVESTOR CONFERENCE CALL TO DISCUSS YEAR-END RESULTS AND 2007 GUIDANCE INTERNET: PHONE NO.: 1-800-525-6384 North America or (780) 409-1668 International CONTACT: Therese Hayes, Bal Bains, Telephone: (604) 707-7000 or 1-800-663-5486 URL: TIME: 09:00 Eastern EVENT: WESTERN OIL SANDS WILL HOST A CONFERENCE CALL AND WEB CAST ON ITS 2006 YEAR END RESULTS INTERNET: PHONE NO.: Dial (416) 644-3421... (Canada Newswire)
UPDATE 1-QLT unit to pay $112.5 mln to settle Eligard suit Feb 12, 2007
Feb 9 (Reuters) - QLT Inc. (QLTI.O: , ) (QLT.TO: , ) said its unit will pay $112. 5 million to settle a patent infringement lawsuit in the United States related to its prostrate cancer drug Eligard. (Reuters)
Canada's QLT, Sanofi Agree to Pay TAP $157.5 to Settle Prostate-Drug Suit Feb 10, 2007
Feb. 9 (Bloomberg) -- Sanofi-Aventis SA, France's biggest pharmaceutical company, and Canadian drugmaker QLT Inc. agreed to pay a total of $157. 5 million to end a patent suit so they can continue to sell the prostate cancer drug Eligard. (Bloomberg -- Canada)
QLT pays up to settle U.S. patent litigation with TAP Feb 10, 2007
VANCOUVER QLT Inc. will pay $112. 5-million (U.S.) to TAP Pharmaceutical Products Inc. to settle a drug patent-infringement lawsuit in the U.S., while Sanofi-Synthelabo will also pay $45-million, for total settlement of $157. (Globe and Mail -- Business)
Canadian Stocks Decline as Oil Shares Drop; Abitibi Gains on Acquisition Jan 30, 2007
QLT Inc. (QLT CN) climbed 53 cents, or 5. 1 percent, to C$10. (Bloomberg -- Canada)
New study reveals higher risk with Genentech drug Jan 27, 2007
The Lucentis data may open marketing opportunities for manufacturers of the competing drugs Visudyne, made by QLT Inc., and OSI Pharmaceuticals' Macugen. Those drugs lost market share after Lucentis was approved in June, based on data demonstrating that it could reverse some vision loss rather than just delay it. (San Francisco Chronicle -- Business)
Drug company QLT says Visudyne sales for Q4 fall 28.7 per cent Jan 20, 2007
TORONTO (CP) - Drug developer QLT Inc. (TSX:QLT) reported another sales drop for its Visudyne eye treatment on Thursday as fourth-quarter results continued to show dwindling movement of the product, its main revenue-driver. Company spokeswoman Bal Bains said increased competition was the main factor for the 28. (CBC News)
QLT's Visudyne sales continue to falter Jan 18, 2007
Vancouver-based pharmaceutical company QLT Inc. reported Thursday that Visudyne sales for the fourth quarter of 2006 declined by 28. 7 per cent from the corresponding period a year earlier. (Globe and Mail -- Business)
QLT USA receives final payment for generic dermatology and manufacturing business Jan 4, 2007
VANCOUVER, Jan. 3 /PRNewswire-FirstCall/ - Further to the Company's press release dated December 22, 2006, QLT Inc. (NASDAQ: ; TSX: QLT) announced today that its wholly-owned subsidiary, QLT USA, Inc., has received, in advance of its due date of the end of the first quarter of 2007, the remaining 40% of the purchase price from the sale of QLT USA's generic dermatology and manufacturing business to Tolmar Inc., a private pharmaceutical company ... About QLT QLT Inc. is a global biopharmaceutical... (PR Newswire)
